Cyclin-Dependent Kinase 4/6 Inhibitors: Is a Noncanonical Substrate the Key Target?
Abstract:
Cyclin-dependent kinases (CDK), such as CDK4 and CDK6, phosphorylate RB1 to release the transcription factor E2F and drive the transition from G1 to S-phase of the cell cycle. Inhibitors of these kinases thereby block cell-cycle progression and presumably exert their therapeutic effect. While this mechanism is straight forward, several aspects have seemed problematic, not the least of which is that these drugs seem to have therapeutic effects on a relatively small number of human cancers. Tong and colleagues took an open-ended approach to this mechanistic question, and their results raise the possibility that inhibition of phosphorylation of the transcription factor p73 is a key mechanism of action of these drugs. They show that p73 inhibition and the resultant upregulation of the cell surface receptor DR5 are necessary for the anticancer effects of CDK4/6 inhibitors, including enhancement of immune-mediated cell killing, and that therapeutic benefit relies largely on their use in conjunction with other agents. While many questions remain to be answered, these findings demonstrate the importance of keeping an open mind to mechanistic aspects of therapeutic agents already in clinical use and highlight how rigorous mechanistic studies can answer both basic and translational questions. See related article by Tong et al., p. 1340.
Insights
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors may work by inhibiting the transcription factor p73, upregulating the DR5 receptor, and enhancing immune-mediated killing. This reveals a new mechanism for CDK4/6 inhibitors in cancer therapy.
Area of Science:
- Cell Biology
- Molecular Oncology
- Cancer Therapeutics
Background:
- Cyclin-dependent kinases (CDK), specifically CDK4 and CDK6, are crucial regulators of the cell cycle, phosphorylating RB1 to facilitate G1 to S-phase transition.
- CDK4/6 inhibitors are used in cancer therapy by blocking cell-cycle progression, but their therapeutic efficacy is limited in a subset of human cancers, suggesting alternative mechanisms of action.
Discussion:
- The study by Tong and colleagues investigates the mechanism of action of CDK4/6 inhibitors, challenging the conventional understanding.
- Their research indicates that inhibition of the transcription factor p73 phosphorylation is a critical, previously unrecognized mechanism.
- This inhibition leads to the upregulation of the cell surface receptor DR5, which is essential for the anticancer effects of CDK4/6 inhibitors.
Key Insights:
- CDK4/6 inhibitors' anticancer effects are linked to p73 inhibition and subsequent DR5 upregulation.
- Enhanced immune-mediated cell killing is a key outcome of this newly identified pathway.
- Therapeutic benefits of CDK4/6 inhibitors are maximized when used in combination with other agents.
Outlook:
- Further research is needed to fully elucidate the complex mechanisms underlying CDK4/6 inhibitor action.
- These findings underscore the importance of exploring novel mechanistic pathways for existing therapeutic agents.
- Rigorous mechanistic studies are vital for advancing both basic science understanding and clinical applications in oncology.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
00:50Anaphase Promoting Complex
01:22PI3K/mTOR/AKT Signaling Pathway
01:25cAMP-dependent Protein Kinase Pathways